KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt issuances (2016 - 2023)

Teva Pharmaceutical Industries filings provide 11 years of Short-Term Debt issuances readings, the most recent being $700.0 million for Q3 2023.

  • On a quarterly basis, Short-Term Debt issuances changed N/A to $700.0 million in Q3 2023 year-over-year; TTM through Dec 2024 was $700.0 million, a 22.22% decrease, with the full-year FY2023 number at $700.0 million, changed N/A from a year prior.
  • Short-Term Debt issuances hit $700.0 million in Q3 2023 for Teva Pharmaceutical Industries, up from $200.0 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $700.0 million in Q3 2023 to a low of -$1.0 million in Q1 2019.
  • Median Short-Term Debt issuances over the past 4 years was $200.0 million (2021), compared with a mean of $245.6 million.
  • Biggest five-year swings in Short-Term Debt issuances: surged 9900.0% in 2019 and later crashed 37.3% in 2021.
  • Teva Pharmaceutical Industries' Short-Term Debt issuances stood at $404.0 million in 2019, then fell by 21.04% to $319.0 million in 2020, then tumbled by 37.3% to $200.0 million in 2021, then soared by 250.0% to $700.0 million in 2023.
  • The last three reported values for Short-Term Debt issuances were $700.0 million (Q3 2023), $200.0 million (Q4 2021), and $319.0 million (Q4 2020) per Business Quant data.